title: Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB.
abstract: The antiinflammatory action of aspirin generally has been attributed to direct inhibition of cyclooxygenases (COX-1 and COX-2), but additional mechanisms are likely at work. These include aspirin's inhibition of NFkappaB translocation to the nucleus as well as the capacity of salicylates to uncouple oxidative phosphorylation (i.e., deplete ATP). At clinically relevant doses, salicylates cause cells to release micromolar concentrations of adenosine, which serves as an endogenous ligand for at least four different types of well-characterized receptors. Previously, we have shown that adenosine mediates the antiinflammatory effects of other potent and widely used antiinflammatory agents, methotrexate and sulfasalazine, both in vitro and in vivo. To determine in vivo whether clinically relevant levels of salicylate act via adenosine, via NFkappaB, or via the "inflammatory" cyclooxygenase COX-2, we studied acute inflammation in the generic murine air-pouch model by using wild-type mice and mice rendered deficient in either COX-2 or p105, the precursor of p50, one of the components of the multimeric transcription factor NFkappaB. Here, we show that the antiinflammatory effects of aspirin and sodium salicylate, but not glucocorticoids, are largely mediated by the antiinflammatory autacoid adenosine independently of inhibition of prostaglandin synthesis by COX-1 or COX-2 or of the presence of p105. Indeed, both inflammation and the antiinflammatory effects of aspirin and sodium salicylate were independent of the levels of prostaglandins at the inflammatory site. These experiments also provide in vivo confirmation that the antiinflammatory effects of glucocorticoids depend, in part, on the p105 component of NFkappaB.
authors.affiliation: New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. cronsb01@mcrcr6.med.nyu.edu
authors.forename: B N
authors.initials: BN
authors.lastname: Cronstein
authors.forename: M C
authors.initials: MC
authors.lastname: Montesinos
authors.forename: G
authors.initials: G
authors.lastname: Weissmann
mesh_terms: D000243:Adenosine Deaminase / Q000378:metabolism; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D002351:Carrageenan; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology; D007527:Isoenzymes / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D016328:NF-kappa B / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D052002:NF-kappa B p50 Subunit; D011451:Prostaglandin-Endoperoxide Synthases / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D011498:Protein Precursors / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D058915:Purinergic P1 Receptor Antagonists; D012459:Salicylates / Q000494:pharmacology*; D012980:Sodium Salicylate / Q000494:pharmacology; D012460:Sulfasalazine / Q000494:pharmacology*; D013805:Theobromine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D005938:Glucocorticoids; D007527:Isoenzymes; D008565:Membrane Proteins; D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; D011498:Protein Precursors; D058915:Purinergic P1 Receptor Antagonists; D012459:Salicylates; D012460:Sulfasalazine; C057837:3,7-dimethyl-1-propargylxanthine; D002351:Carrageenan; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C496512:Ptgs1 protein, mouse; D000243:Adenosine Deaminase; D013805:Theobromine; D001241:Aspirin; D012980:Sodium Salicylate